TCRab
-CD5 þ CD1a þ T cells were mixed with CD4 þ CD8 þ cells and more mature CD4 þ CD8 ¹ TCRab þ cells. However, in FTOC initiated with bone marrow T progenitors, <10% double-positive cells were observed, whereas this proportion increased to 50% when cord blood CD34 þ cells were used, and most CD4 þ cells were immature T cells. These differences may be explained by a lower frequency of T-cell progenitors in adult samples, but may also suggest differences in the thymic signals required by bone marrow versus cord blood T progenitors. Finally, since cytokine-stimulated CD34 þ CD38 low cells retained their ability to generate T cells, these FTOC assays will be of value to monitor, when combined with other biological assays, the influence of different expansion protocols on the potential of human stem cells.
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Evaluation of the haemopoietic potential of human donor cells in transplantation protocols is usually based on the quantitation of colony-forming cells (CFC) and long-term culture initiating cells (LTC-IC) (Sutherland et al, 1989) in vitro, and more recently human cells reconstituting NOD-SCID recipients Conneally et al, 1997; Pflumio et al, 1996; Wang et al, 1997) . Except for the in vivo NOD-SCID assay, which detects both B-lymphoid and myeloid progenitors, most of the in vitro assays identify an exclusive myeloid differentiation, and only during the past years have in vitro conditions been designed which successfully allow human CD34 þ CD38 low cells to differentiate into CD19 þ pro-B cells (Berardi et al, 1997; Hao et al, 1998; Galy et al, 1995a; Rawlings et al, 1997) , and CD56 þ NK cells (Carayol et al, 1998) . However, the identification of the T-cell potential of human pluripotent stem cells has remained a major obstacle both in vitro and in vivo. Feeders of thymic stromal cells do not reproducibly support T-cell differentiation in vitro (Rosenzweig et al, 1996) and the most successful strategy so far is based on the colonization by test cells of intact human or murine embryonic thymic lobes, which are then either kept in in vitro organotypic culture (fetal thymic organ culture; FTOC) (Jenkinson & Anderson, 1994; Merkenschlager et al, 1992) or grafted into a SCID recipient (Barcena et al, 1994; Galy et al, 1995b; Péault et al, 1991) . Yeoman et al, 1993) FTOC have enabled the identification of T-cell progenitors among adult as well as fetal human CD34 þ suspensions. In murine thymus, however, cell proliferation was lower than in human FTOC, and the production of singlepositive CD8
þ cells was compromised because murine class I molecules are poor effectors of the CD8 selection. Nevertheless, these studies demonstrated that human T-lymphoid differentiation could proceed in a murine thymic environment in vitro and recent data suggest that this might occur also in vivo in NOD-SCID recipients (van der Loo et al, 1998; Yurasov et al, 1997) . Since active human B lymphopoiesis and myelopoiesis take place in vivo in NOD-SCID mice Kollmann et al, 1994; Pflumio et al, 1996; Vormoor et al, 1994) , and in vitro in the presence of murine stromal feeders (Berardi et al, 1997; Galy et al, 1995a; Rawlings et al, 1997) , one can conclude that a murine environment can support the differentiation of primitive human haemopoietic cells in all lymphoid and myeloid pathways at least when cells from a fetal source are used.
We have previously described in vitro conditions suitable for B-lymphoid, NK and myeloid differentiation of CD34 þ CD38 low human cells (Berardi et al, 1997; Carayol et al, 1998; Croisille et al, 1994) . These were based on the coculture of human cells with a murine stromal cell line in the presence of selected human cytokines. Since identification of stem cells requires assessment of their T-cell potential, we investigated in this study the capacity of embryonic thymic lobes from NOD-SCID mice to support T-cell differentiation from human CD34 þ cells. We report that NOD-SCID FTOC cultures reproducibly identify T-cell progenitors in both CD34 þ CD38 low and CD34 þ CD38 þ cells from adult bone marrow and cord blood. These progenitors differentiated following the orderly sequence of events which occurs in human thymus. We further show that a short stimulation of CD34 þ CD38 low cells by a combination of cytokines including IL-3 did not alter their T-cell potential, an observation which may be clinically relevant. Mouse/ human hybrid FTOC therefore emerge as a useful tool to add to the panel of biological assays developed to assess the full lymphoid and myeloid differentiative potential of primitive human stem cells.
MATERIALS AND METHODS
Mice. NOD-LtSz-scid/scid (hereafter called NOD-SCID) were originally obtained from Dr John Dick (Hospital for Sick Children, Toronto, Ontario, Canada). Mouse breeding pairs were housed in the animal facilities of the Institut Gustave Roussy under sterile conditions in air-filtered containers. 14-16 d pregnant NOD-SCID mice were used in most of the experiments. The age of development of the embryos was calculated taking as day 0 the morning on which the mating plug was observed. In experiments performed by microinjection, thymuses from newborn mice were used.
Collection and fractionation of human cord blood (CB), bone marrow (BM) and mobilized peripheral blood (PB) mononuclear cells (MNC) . Cord blood samples from full-term newborns were collected (Hospital Saint-Vincent de Paul, Paris, France) with the informed consent of the mothers. Samples were diluted 1:2 in PBS without magnesium (¹Mg) and calcium (¹Ca) prior to separation over Ficoll/Hypaque (Lymphoprep, Nyegaard, Oslo; density 1·077 g/ml). All further manipulations of low-density CB-MNC were done in PBS-0·5% BSA. Low-density CB-MNC were subjected to a standard CD34 immunomagnetic bead separation using the miniMACS system following the manufacturer's guidelines (Miltenyi Biotec, Calif.) . Bone marrow cells were extracted from bone fragments collected during surgery for hip replacement as previously described (Croisille et al, 1994) and CD34 þ cells were obtained from light-density cell suspensions following the procedure described above for cord blood specimens. In order to exclude contamination of the purified CD34 þ CD38 low cells were incubated with murine thymic lobes immediately after their purification. In some experiments CD34 þ CD38 low cells were incubated for 7 d with murine stromal MS-5 cells (Itoh et al, 1989 ) and cytokines; FTOC were initiated with CD34 þ cells sorted from the cultured cells. In these experiments, recombinant (r) human (hu) cytokines included rhuSCF (stem cell factor, 20 ng/ml, kindly provided by Amgen, Thousands Oaks, Calif., U.S.A.), rhu-IL-3 (2-100 ng/ml), rhu-IL-6 (100 U/ml), rhu-GM-CSF (granulocyte-macrophage colony-stimulating factor, 10 ng/ ml), PEG-rhu MGDF (megakaryocyte growth and differentiation factor,10 ng/ml, kindly provided by Amgen, Thousands Oaks, Calif.), rhu-Flt3-L (10 ng/ml), rhu-IL-2 (5 ng/ml) and rhu-IL-7 (20 ng/ml) (all from Diaclone, Besançon, France).
Fetal thymic organ culture (FTOC) . FTOC cultures were done as initially described by Jenkinson & Anderson (1994) and Merkenschlager & Fisher (1992) , except that thymi were collected from NOD-SCID mice. Since the SCID mutation blocks T-cell development in NOD-SCID mice at an early stage, removal of the endogenous population of thymocytes was unnecessary.
Colonization of the thymic tissue by human cells was facilitated by the hanging-drop procedure. Each thymic lobe was incubated in Terasaki wells for 2 d in 25 ml of complete medium: RPMI 1640 supplemented with 10% heat-inactivated human serum, 5% fetal calf serum (FCS, Stem Cell Technologies, Vancouver, Canada), 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine. 10-50 000 CD34 þ cells purified from cord blood or bone marrow were added to each well. The plates were immediately inverted to allow the formation of hanging drops and incubated undisturbed in a humidified incubator (5% CO 2 in air, 37ЊC). After 48 h, thymic lobes were transferred onto floating nucleopore filters (Isopore membrane, 25 mm in diameter, pore size 8 mm, Millipore SA, France) in six-well plates in 2·5 ml of complete medium and cultured for 28-35 d at 37ЊC in air supplemented with 5% CO 2 with a weekly medium change. Cytokines [rhu-IL-2 (5 ng/ml), 20 ng/ml rhu-IL-7 and 50 ng/ml rhu-SCF] were included only during the first 48 h, essentially to prevent loss of human cells by apoptosis (Kondo et al, 1997) and to promote the survival of early T-cell progenitors (Akashi et al, 1997) .
At the end of the culture period, human cells were recovered from the thymic lobes by mechanical disruption of the tissue between two sieves. Initial experiments showed that this procedure extracted most viable cells from the thymus. Cells extracted from the different lobes were pooled except in limiting dilution experiments where lobes were individually processed.
Phenotype of human cells collected from cultured thymic lobes. Pooled cells extracted from thymic lobes were incubated with the following murine MoAbs recognizing human antigens and coupled to phycoerythrin (RPE), fluorescein isothyocyanate (FITC) or PE-Cy-5. The MoAbs used recognized the following human antigens: CD45 (CD45-FITC, Immunotech), CD4 (CD4-FITC, Pharmingen; CD4-PE, Becton Dickinson; CD4-PE-Cy-5, Pharmingen), CD8 (CD8-FITC, Becton Dickinson; CD8-PE, Pharmingen), CD3 (CD3-FITC, Immunotech and Coulter), TCR ab (TCR ab-PE, Immunotech), TCR gd (TCR gd-PE, Immunotech), CD7 (CD7-FITC, CD7-PE, both from Pharmingen), CD34 (CD34-FITC, Immunotech; CD34-PE, Becton Dickinson), CD38 (CD38-FITC, Immunotech), CD1a (CD1a-PE, Cymbus Bioscience), CD56 (CD56-PE, Immunotech; CD56-PE-Cy-5, Immunotech), CD19 (CD19-PE, Becton Dickinson), CD11b (CD11b-FITC, Immunotech), CD13 (CD13-FITC, Immunotech), CD14 (CD14-PE, Immunotech), CD36 (CD36-FITC, Immunotech) and CD33 (CD33-FITC and CD33-PE, Cymbus Bioscience). Lack of reactivity of the mouse anti-human MoAbs with NOD-SCID murine cells was ruled out in pilot experiments by labelling either marrow or thymic cells from untreated NOD-SCID mice with the above MoAbs. The morphological characteristics of mouse Tprecursor cells were defined by staining with antibodies specific for murine antigens. Background levels were measured using isotypic controls. Analysis was done on a FACS-Sort (Becton Dickinson). When two-colour labelling was performed, compensation was set up with single-stained samples. Low forward scatter elements were excluded from the analysis by gating them out and 10 000 events were collected and analysed using the Cellquest software (Becton Dickinson). Labelling was performed in 50 ml of a-MEM/10% FCS for 20 min on ice. In some experiments the intracytoplasmic expression of CD3 was determined using a cell permeabilization kit (Harlan, Sera-Lab Ltd, Crawley Down). Negative controls included cells processed simultaneously and incubated with a non-relevant IgG.
RESULTS

NOD-SCID FTOC support the differentiation of human CD34
þ , CD34 þ CD38 low and CD34 þ CD38 þ T-cell progenitor cells In a first series of experiments we showed the equal ability of FTOC established with deoxyguanosine-depleted thymic lobes from immune competent (C57BL × Balb-C) or with untreated lobes from immune deficient (SCID and NOD-SCID) murine 
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þ cells were observed. † Numbers show the number of nucleated cells/lobe calculated from the total number of nucleated cells recovered from all the pooled thymic lobes divided by the total number of lobes.
‡ Cells were analysed in the lymphoid gate (defined in Fig 1) . Numbers represent the mean (ϮSEM) % of human cells determined in the indicated number of positive experiments.
§ The proportion of CD4 þ CD8 þ cells in the total CD4 þ fraction was calculated. ¶ When results were from fewer than three experiments mean and SEM were not calculated and raw data are shown. embryos to support the development of double-positive CD4 þ CD8 þ cells from cord blood CD34 þ cells (data not shown). For practical reasons, all further experiments were performed with NOD-SCID thymuses.
In nine separate experiments we assessed the capacity of embryonic thymic lobes from day 14 NOD-SCID embryos to support T-cell development from cord-blood-derived CD34 þ cells (Table I) . Usually 10-15 thymic lobes were seeded per experiment, and each lobe was incubated with 20-50 000 sorted CD34 þ cells. After 30 d an average of 20 000 nucleated cells was recovered per lobe, 60% of which were labelled with an anti-human CD45 antibody. Even though these numbers were below the numbers of input cells, since only a few of these CD34 þ cells entered into the thymus (Plum et al, 1994) , active cell proliferation probably occurred. CD4 þ cells were recovered in each experiment and represented 49·4 Ϯ 5·4% (range 28·4-82%) of nucleated cells. Half (43·5 Ϯ 10%, range 4·5-82%) of these were double-positive (DP) CD4 þ CD8 þ cells (Table I  and Fig 1A) . Single-positive CD4 þ cells included a majority of immature T cells prior to the DP stage and a minority of mature T cells (see below detailed phenotypic analysis).
In order to determine whether T-cell progenitors were also present in the CD34 þ CD38 low fraction which is enriched in primitive B lymphoid and myeloid progenitors (Berardi et al, 1997; Croisille et al, 1994) , we initiated FTOC experiments with CD38 low cells (10-15 000 cells/lobe) (n ¼ 7) and the corresponding CD38 þ cells (10-15 000 cells/lobe) (n ¼ 6) separately. Cells were incubated with two different combinations of human recombinant cytokines during the 48 h of hanging drop: either IL-2, IL-7 and SCF (n ¼ 5) or the same three plus IL-3, GM-CSF, IL-6, PEG-rhu-MGDF and Flt3-L (n ¼ 2). Since both cocktails yielded similar results, the results were pooled. As shown in Table I , in 6/7 experiments where NOD-SCID FTOC were seeded with CD38 low cells (Fig 1B) and in all six experiments seeded with CD34 þ CD38 þ cells (Fig 1C) þ CD38 þ cells (Table I  and Fig 1C) . Thus these results demonstrated that progenitors with the ability to differentiate along the T-cell pathway in NOD-SCID FTOC existed in both CD34 þ
CD38
þ and CD34 þ CD38 low cord blood suspensions. However, some differences were noted depending on the phenotype of input cells. First, the proportion of CD4 low (mean fluoresence intensity MFI <100) within the CD4 þ population was higher in FTOC seeded with CD38 low cells (31·3 Ϯ 7·6%) than in experiments performed with CD38 þ (16·4 Ϯ 3·2%) or CD34 þ cells (22·2 Ϯ 4·6%). Second, as mentioned above, the proportion of CD4 þ CD8 þ cells within the total CD4 þ fraction was higher when FTOC were initiated with CD38 þ CD8 þ cells (Fig 2A) . Out of 18 lobes initiated with 500 cells, 11 contained CD4 þ cells and seven CD4 þ CD8 þ cells ( Figs 2C and 2D) , and CD4 þ CD8 þ cells were detected in 3/19 lobes seeded with 100 cells (Fig 2E) . Based on these results, we calculated that 1/500 CD34 þ cord blood cells would give rise to T cells in FTOC. However, since many steps were uncontrolled in these FTOC, such as the number of CD34 þ cells effectively entering the thymus or the requirement for accessory cells, this frequency was likely to be underestimated. This was suggested by preliminary results which showed that the addition of 5000 irradiated CD38 þ cells to 100 CD34 þ test cells improved the proportion of positive lobes [5/10 lobes seeded were positive, three contained CD4 þ CD8 þ cells (Figs 2F) and the other two contained CD4
Estimation of the frequency of T-cell progenitors among CD34
bright cells].
Identification of T-cell progenitors in the CD34
þ CD38 low and CD34 þ CD38 þ fractions of adult bone marrow In five separate experiments NOD-SCID thymic lobes were incubated with CD34 þ adult marrow cells in conditions similar to those designed for FTOC experiments performed with cord blood cells. As shown in Table I, CD4 þ CD8 þ cells were detected in only four of these five experiments. Within the CD4 þ population the proportion of CD4 þ CD8 þ cells was low (10 Ϯ 2%) when compared to that observed for cord blood experiments (43·5 Ϯ 10%) ( Table I , and Fig 3A) . In two experiments both CD34 þ CD38 low ( Fig 3B) and CD34 þ CD38 þ (Fig 3C) cells incubated in hanging drop with NOD-SCID thymic lobes led to similarly low proportions (<20%) of CD4 þ
CD8
þ cells (Table I) . Interestingly, the þ cells from cytokinemobilized peripheral blood and the proportion of CD4 þ in these thymuses was constantly below 10% (data not shown).
Human T-cell differentiation within NOD-SCID thymuses recapitulates the normal steps of human thymopoiesis
In order to evaluate whether human T-cell differentiation in NOD-SCID thymic lobes proceeded through the same ordered sequence as that described in the human thymus, we performed a detailed phenotype of cells collected from thymic lobes reconstituted with cord blood-or bone marrow-derived CD34 þ cells. Results are illustrated in Fig 4 and Table II . A detailed phenotypic analysis of T cells recovered from FTOC could not be performed in each experiment because numbers of cells collected were too low, but the expression of the Tcell-specific markers CD4, CD8, TCRab and CD3 was systematically examined. Three stages of maturation were recognized: a CD4 þ CD8 ¹ immature stage, preceeding the DP CD4 þ CD8 þ stage, and a small compartment of positively selected mature CD4 þ CD8 ¹ lymphocytes. Most CD4 þ CD8 ¹ cells coexpressed CD1a (92%, n ¼ 1), CD5 (40 Ϯ 18%, range 16-94%, n ¼ 4), CD38 (99%, n ¼ 1) and intracytoplasmic CD3 (100%, n ¼ 3), thus proving their 
CD8
¹ cells expressed CD34 (1·2%, n ¼ 1), and TCRgd (2·3%, n ¼ 1). CD7 was expressed on 32 Ϯ 8% of CD4 þ cells (n ¼ 4), but CD25 and CD69 were not present. These cells most probably correspond to the
¹ TCRab ¹ immature SP stage prior to the DP CD4 þ CD8 þ previously described in the human thymus (Hori et al, 1991) . CD11b (n ¼ 6), CD13, CD14, CD33 and CD36 were not coexpressed by CD4 þ cells thus excluding that some CD4 low cells belong to the granulomonocytic lineage.
Fewer than 10% CD4 þ T cells were mature selected T cells, which expressed TCR ab (2·8 Ϯ 0·4%, range 1-4%, n ¼ 6) and sCD3 (8 Ϯ 3%, range 2·4-20%, n ¼ 5). Single-positive CD8 þ cells were not detected, as previously reported in these human/mouse hybrid FTOC. CD4 þ CD8 þ cells included both TCRab-positive (69 Ϯ 12%, n ¼ 6) and sCD3-positive (64 Ϯ 7·5%, n ¼ 5) cells and TCRab-negative cells. Both subsets, probably representing successive maturation stages, were found in all experiments (Table II and Fig 4) . Almost all CD4 þ CD8 þ cells coexpressed CD5 (86 Ϯ 4%, range 77-96%, n ¼ 4), CD1a (99·5%, n ¼ 1) and CD38 (96·5%, n ¼ 1). Only rare DP cells expressed CD34 (4%, n ¼ 1), or TCRgd (1·8%, n ¼ 1).
Although all three stages of T-cell maturation were detected in FTOC seeded by cord blood and bone marrow cells, FTOC initiated with adult marrow cells yielded a lower proportion of CD4 þ CD8 þ than FTOC initiated with cord blood CD34 þ cells (10% v 45% respectively, see Table I and Figs 1 and 3) . Second, most CD4 þ cells produced by bone marrow CD34 þ cells and their CD38 low or CD38 þ subsets expressed intermediate or low levels of CD4 (MFI 5 × 10 1 ) in contrast to the bright CD4 þ staining observed in FTOC seeded with cord blood cells ( Figs 1A and 3A) . CD34 þ CD4 ¹ human cells were present in a significant proportion in all experiments seeded with cord blood CD34 
* Numbers refer to the mean (Ϯ SEM) proportion of CD4
¹ cells co-expressing the indicated marker. † n indicates the number of experiments. 
CD38
low cells isolated from human cord blood and adult bone marrow and used either fresh or after 7 d of prestimulation with human cytokines.
Experiment
Percentage of cells (mean ϮSEM) ‡ Fresh  3/3  a  17 000  76·1  56·5  68·3  1·8  b  4700  nd  22·1  13·3  0  c  2800  nd  18·4  5·4  0   Cultured §  3/3  a  7300  39·8  26·8  24·3  3·8  b  8500  60·8  43·3  27·7  0  c  4900  46·2  31 
Short-term treatment with IL-3 and human cytokines does not abrogate the T-cell potential of CD34
þ CD38 low cells In the next series of experiments we investigated whether Tcell potential could be maintained in conditions which promote cell expansion, i.e. in the presence of cytokines. More specifically, we assessed the influence on the development of human T-lymphoid progenitor cells of interleukin-3, since in the mouse this cytokine abrogated expression of the lymphoid potential (Ball et al, 1996; Hirayama & Ogawa, 1995) . In seven experiments (four performed with adult marrow and three with cord blood), CD34
þ CD38 low cells were incubated with a combination of eight cytokines (including 2 ng/ml IL-3) in the presence of stromal cells previously shown to support lymphoid differentiations (Berardi et al, 1997; Carayol et al, 1998) . After 1 week in culture, we observed an average 40-50-fold expansion in total nucleated cells and a 10-fold expansion in the numbers of CD34 þ cells. CD34 þ cells were sorted and used to initiate FTOC experiments as described for fresh cells. As indicated in Table III (Table III) . It is therefore difficult to conclude on the maintenance of T-cell potential after cytokine stimulation of marrow CD34 þ CD38 ¹ cells. Finally, we ruled out a deleterious effect of IL-3 on the development of T cells in two FTOC experiments initiated with cells cultured with high concentrations of IL-3 (up to 100 ng/ml). This indicated that IL-3 had no inhibitory effect on T-cell differentiation, an observation which was in agreement with our additional data on the lack of inhibition of IL-3 on the production of both B cells and NK cells from CD34 þ CD38 ¹ progenitors (data not shown).
DISCUSSION
A major obstacle to the identification of the full differentiative potential of candidate stem cells is the lack of an assay that will support simultaneous differentiation in all lymphoid and myeloid pathways. We (Berardi et al, 1997) and others (Baum et al, 1992; Galy et al, 1995a; Hao et al, 1998) have shown that myeloid and B-lymphoid potentials can be simultaneously expressed in vitro from human single cells, but expression of the T-cell potential of these cells remains difficult to assess, although not impossible, as recently shown in the mouse (Kawamoto et al, 1997; Kondo et al., 1997) . In this study we have shown that NOD-SCID FTOC offers a very reproducible system to monitor in vitro the T-cell potential of various human stem cell fractions, even from as low as 100 cells. Thus CD34 þ , CD34 þ CD38 low and CD34 þ CD38 þ cells from both adult marrow and cord blood differentiated into T cells in NOD-SCID FTOC, and at least 0·02% of cord blood CD34 þ were T-cell progenitors. Phenotypic analysis of the produced T cells revealed both et al, 1991; Kraft et al, 1993) including TCRab þ and TCRab ¹ subsets. This indicated that the initial steps of T-cell differentiation which occur in murine FTOC reproduce those found during normal human thymocyte differentiation (Kisielow & Von Boehmer, 1995; Spits et al, 1995) . However, in these hybrid FTOC further positive selection resulting in the production of mature single positive T cells sCD3
þ was compromised by the poor reactivity of murine class I and to a lesser degree class II molecules with human cells (Blom et al, 1997) .
Our rationale for using the NOD-SCID strain was based on accumulating evidence that NOD-SCID mice are the most sensitive recipients for transplantable human cells with multiple potentials Pflumio et al, 1996) and are particularly suitable for human B-lymphoid differentiation (Hogan et al, 1997; Pflumio et al, 1996) , and may also support T-cell differentiation in vivo (van der Loo et al, 1998; Yurasov et al, 1997) . Furthermore, the successful development of T cells from fetal liver and cord blood progenitors in murine FTOC has been demonstrated. Thymic tissue from both immune competent and immune deficient embryonic mice (Blom et al, 1997; Plum et al, 1994; Res et al, 1996; Yeoman et al, 1993) has been used, and while this study was in progress unambiguous demonstration that CD34 þ CD38 ¹ and CD34 þ CD38 þ cord-blood-derived cells differentiate into T cells in hybrid mouse/human FTOC has been shown (Blom et al, 1997; Verhasselt et al, 1998) . We confirm here that the FTOC procedure, using murine thymus, offers a useful in vitro alternative to the in vivo SCID-hu assay, which was the first to convincingly identify the T-cell potential of human primitive progenitor cells (Barcena et al, 1993; DiGustio et al, 1994; Galy et al, 1995b; Galy et al, 1994; Péault et al, 1991) .
In contrast to the abundant litterature on the lymphoid potential of fetal cells, very little is known regarding the lymphoid potential of primitive progenitors from adult tissues. We have shown for the first time that both CD34 þ CD38 low and CD38 þ subsets from adult marrow could develop into T cells in NOD-SCID FTOC, whereas mobilized peripheral-blood-derived cells did not.
However, T-cell differentiation from adult marrow CD34 þ cells was less efficient than from cord blood CD34 þ cells. Thus, a low proportion (ϳ10%) of CD4 þ CD8 þ cells was recovered from thymic lobes after 35 d in culture and the expression of CD4 was low as compared to the bright CD4 labelling of T cells derived from cord blood CD34 þ cells. Preincubation of marrow CD38 low cells with cytokines for 7 d did not improve these results (and even suggested a decrease in T-cell potential after cell stimulation, in contrast to the maintenance of T-cell potential in similar experiments performed with cord blood cells). Two parameters might contribute to these differences: first it is probable that the frequency of T-progenitor cells is lower in adult populations than in their fetal counterparts, a hypothesis which is supported by the data obtained by Galy et al (1995) and Plum et al (1994) . Lower frequencies of all categories of primitive progenitor cells in adult haemopoietic tissues when compared to fetal or neonatal tissues have been largely documented in a wide variety of biological assays, both in mouse (Pawliuk et al, 1996) and man (Lansdorp et al, 1993) , including in the in vivo NOD-SCID-SRC/CRU assay (Conneally et al, 1997; Wang et al, 1997) . Thus, in our experience 8-10% of CD34 þ CD38 low cord blood cells but <0·05% of CD34 þ CD38 low adult bone marrow cells are bipotent B-lymphoid-myeloid progenitors (Berardi et al, 1997) . Second, it is also possible that important signals required by adult human T-cell progenitors, but not fetal progenitors, are lacking in the NOD-SCID thymic environment. This might explain why we failed to detect T cells in NOD-SCID FTOC initiated with adult peripheral blood CD34 þ cells, whereas these cells generated high numbers of CD4 þ CD8 þ cells in the SCID-hu assay , which suggests that additional signals are delivered by the human thymus environment. Alternatively, accessory cells present within CD34
þ cord blood cells, but not adult CD34 þ cells, may also play a role, such as dendritic cells which are the predominant population early during the culture (Plum et al, 1994; Verhasselt et al, 1998) .
Finally, we also showed that in conditions where active cell divisions occur, cord-blood-derived CD34 þ CD38 ¹ cells did not immediately lose their T-cell potential. Importantly, IL-3, which in the murine system has been reported to inhibit Tlymphoid and B-lymphoid differentiation of murine stem cells (Ball et al, 1996; Hirayama & Ogawa, 1995) , had no such effect on human lymphoid differentiation, neither in the T cell (this study) nor B or NK differentiation pathways (unpublished observations). This suggests that early stem cells may be successfuly amplified without a major loss of potential, and NOD-SCID FTOC may therefore prove an invaluable additional tool to investigate the function of human stem cells subjected to treatment with regulatory molecules.
